search
Back to results

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Canagliflozin 100 mg
Canagliflozin 300 mg
Metformin XR
Sponsored by
Janssen Research & Development, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, Type 2, Diabetes Mellitus, Canagliflozin (JNJ-28431754), Metformin

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must have type 2 diabetes mellitus with inadequate glycemic control on diet and exercise
  • Not on antihyperglycemic agent therapy (at least 12 weeks before screening) and have a screening visit fingerstick glycated hemoglobin (HbA1c) of more than or equal to 7 percent and less than or equal to 12.5 percent
  • Have a screening visit HbA1c of more than or equal to 7.5 percent and less than or equal to 12 percent as determined by the central laboratory
  • Must have a fasting plasma glucose of less than or equal to 300 mg/dL (16.7 mmol/L) prior to randomization
  • Must have a fasting fingerstick glucose of greater than 120 mg/dL (6.7 mmol/L) performed at home or at the study center prior to randomization

Exclusion Criteria:

  • History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • Fasting C-peptide less than 0.70 ng/mL (0.23 nmol/L) in participants for whom the investigator cannot reasonably exclude T1DM based upon clinical evaluation
  • Repeated (2 or more over a 1 week period) fasting self-monitored blood glucose measurements more than 300 mg/dL (16.7 mmol/L) prior to randomization, despite reinforcement of diet and exercise counseling
  • History of hereditary glucose-galactose malabsorption or primary renal glucosuria
  • Has history of, or currently active, illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Canagliflozin 100 mg

Canagliflozin 300 mg

Metformin XR

Canagliflozin 100 mg + Metformin XR

Canagliflozin 300 mg + Metformin XR

Arm Description

Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.

Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.

Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.

Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.

Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.

Outcomes

Primary Outcome Measures

Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26
The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups.

Secondary Outcome Measures

Percent Change in Body Weight From Baseline to Week 26
The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups.
Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26
The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups.
Change in Systolic Blood Pressure From Baseline at Week 26
The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups.
Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups.
Percent Change in Triglycerides From Baseline to Week 26
The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups.
Number of Participants With Treatment Emergent Adverse Events (AEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.

Full Information

First Posted
March 8, 2013
Last Updated
June 12, 2017
Sponsor
Janssen Research & Development, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01809327
Brief Title
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Official Title
A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
June 4, 2013 (Actual)
Primary Completion Date
December 2, 2014 (Actual)
Study Completion Date
December 2, 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Janssen Research & Development, LLC

4. Oversight

Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite treatment with diet and exercise. The safety and tolerability of canagliflozin will also be assessed.
Detailed Description
This study will be a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), active-controlled (one of the treatments is an established effective treatment for type 2 diabetes mellitus), parallel-group (each group of participants will be treated at the same time), 5-arm (groups), multicenter study. Approximately 1,200 participants will be randomly assigned to the 5 treatment arms in a 1:1:1:1:1 ratio for 26 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus, Type 2, Diabetes Mellitus, Canagliflozin (JNJ-28431754), Metformin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1186 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Canagliflozin 100 mg
Arm Type
Experimental
Arm Description
Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
Arm Title
Canagliflozin 300 mg
Arm Type
Experimental
Arm Description
Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
Arm Title
Metformin XR
Arm Type
Experimental
Arm Description
Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
Arm Title
Canagliflozin 100 mg + Metformin XR
Arm Type
Experimental
Arm Description
Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
Arm Title
Canagliflozin 300 mg + Metformin XR
Arm Type
Experimental
Arm Description
Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
Intervention Type
Drug
Intervention Name(s)
Canagliflozin 100 mg
Intervention Description
One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
Intervention Type
Drug
Intervention Name(s)
Canagliflozin 300 mg
Intervention Description
One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
Intervention Type
Drug
Intervention Name(s)
Metformin XR
Intervention Description
One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
Primary Outcome Measure Information:
Title
Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26
Description
The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups.
Time Frame
Day 1 (Baseline) and Week 26
Secondary Outcome Measure Information:
Title
Percent Change in Body Weight From Baseline to Week 26
Description
The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups.
Time Frame
Day 1 (Baseline) and Week 26
Title
Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26
Description
The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups.
Time Frame
Week 26
Title
Change in Systolic Blood Pressure From Baseline at Week 26
Description
The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups.
Time Frame
Day 1 (Baseline) and Week 26
Title
Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
Description
The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups.
Time Frame
Day 1 (Baseline) and Week 26
Title
Percent Change in Triglycerides From Baseline to Week 26
Description
The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups.
Time Frame
Day 1 (Baseline) and Week 26
Title
Number of Participants With Treatment Emergent Adverse Events (AEs)
Description
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
Time Frame
Up to 30 weeks of last study drug administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must have type 2 diabetes mellitus with inadequate glycemic control on diet and exercise Not on antihyperglycemic agent therapy (at least 12 weeks before screening) and have a screening visit fingerstick glycated hemoglobin (HbA1c) of more than or equal to 7 percent and less than or equal to 12.5 percent Have a screening visit HbA1c of more than or equal to 7.5 percent and less than or equal to 12 percent as determined by the central laboratory Must have a fasting plasma glucose of less than or equal to 300 mg/dL (16.7 mmol/L) prior to randomization Must have a fasting fingerstick glucose of greater than 120 mg/dL (6.7 mmol/L) performed at home or at the study center prior to randomization Exclusion Criteria: History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy Fasting C-peptide less than 0.70 ng/mL (0.23 nmol/L) in participants for whom the investigator cannot reasonably exclude T1DM based upon clinical evaluation Repeated (2 or more over a 1 week period) fasting self-monitored blood glucose measurements more than 300 mg/dL (16.7 mmol/L) prior to randomization, despite reinforcement of diet and exercise counseling History of hereditary glucose-galactose malabsorption or primary renal glucosuria Has history of, or currently active, illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janssen Research & Development, LLC Clinical Trial
Organizational Affiliation
Janssen Research & Development, LLC
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Encinitas
State/Province
California
Country
United States
City
Newport Beach
State/Province
California
Country
United States
City
Northridge
State/Province
California
Country
United States
City
Norwalk
State/Province
California
Country
United States
City
Rancho Cucamonga
State/Province
California
Country
United States
City
Walnut Creek
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Northglenn
State/Province
Colorado
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
New Port Richey
State/Province
Florida
Country
United States
City
Opa-locka
State/Province
Florida
Country
United States
City
Perry
State/Province
Georgia
Country
United States
City
Evansville
State/Province
Indiana
Country
United States
City
Mandeville
State/Province
Louisiana
Country
United States
City
Metairie
State/Province
Louisiana
Country
United States
City
Sunset
State/Province
Louisiana
Country
United States
City
Flint
State/Province
Michigan
Country
United States
City
Kalamazoo
State/Province
Michigan
Country
United States
City
Royal Oak
State/Province
Michigan
Country
United States
City
Troy
State/Province
Michigan
Country
United States
City
Olive Branch
State/Province
Mississippi
Country
United States
City
Picayune
State/Province
Mississippi
Country
United States
City
Albuquerque
State/Province
New Mexico
Country
United States
City
West Seneca
State/Province
New York
Country
United States
City
Hickory
State/Province
North Carolina
Country
United States
City
Mooresville
State/Province
North Carolina
Country
United States
City
Franklin
State/Province
Ohio
Country
United States
City
Mason
State/Province
Ohio
Country
United States
City
Perrysburg
State/Province
Ohio
Country
United States
City
Zanesville
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Yukon
State/Province
Oklahoma
Country
United States
City
Tualatin
State/Province
Oregon
Country
United States
City
Fleetwood
State/Province
Pennsylvania
Country
United States
City
Norristown
State/Province
Pennsylvania
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
Rapid City
State/Province
South Dakota
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Bellaire
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Pearland
State/Province
Texas
Country
United States
City
Plano
State/Province
Texas
Country
United States
City
Bountiful
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
Danville
State/Province
Virginia
Country
United States
City
Norfolk
State/Province
Virginia
Country
United States
City
Richmond
State/Province
Virginia
Country
United States
City
Buenos Aires
Country
Argentina
City
Ciudad Autonoma Buenos Aires
Country
Argentina
City
Ciudad Autonoma De Buenos Aires
Country
Argentina
City
Cordoba
Country
Argentina
City
Mar Del Plata
Country
Argentina
City
Moron
Country
Argentina
City
Rosario
Country
Argentina
City
Zarate
Country
Argentina
City
Passo Fundo
Country
Brazil
City
Sao Paulo
Country
Brazil
City
São Paulo
Country
Brazil
City
Kromeriz
Country
Czechia
City
Pardubice
Country
Czechia
City
Praha 8
Country
Czechia
City
Praha
Country
Czechia
City
Unicov
Country
Czechia
City
Balatonfured
Country
Hungary
City
Budapest
Country
Hungary
City
Eger
Country
Hungary
City
Szikszó
Country
Hungary
City
Zalaegerszeg
Country
Hungary
City
Goyang-Si
Country
Korea, Republic of
City
Seoul
Country
Korea, Republic of
City
Suwon
Country
Korea, Republic of
City
Celaya
Country
Mexico
City
Durango
Country
Mexico
City
Guadalajara
Country
Mexico
City
Mexico
Country
Mexico
City
Monterrey
Country
Mexico
City
Pachuca De Soto
Country
Mexico
City
Tampico
Country
Mexico
City
Carolina
Country
Puerto Rico
City
Ponce
Country
Puerto Rico
City
San Juan
Country
Puerto Rico
City
Trujillo Alto
Country
Puerto Rico
City
Bacau
Country
Romania
City
Brasov
Country
Romania
City
Bucharest
Country
Romania
City
Bucuresti
Country
Romania
City
Oradea
Country
Romania
City
Tg Mures
Country
Romania
City
Arkhangelsk
Country
Russian Federation
City
Barnaul
Country
Russian Federation
City
Chelyabinsk
Country
Russian Federation
City
Kemerovo
Country
Russian Federation
City
Moscow
Country
Russian Federation
City
Penza
Country
Russian Federation
City
Rostov-On-Don
Country
Russian Federation
City
Saint Petersburg
Country
Russian Federation
City
Saint-Petersburg
Country
Russian Federation
City
Samara
Country
Russian Federation
City
Saratov
Country
Russian Federation
City
Smolensk
Country
Russian Federation
City
St Petersburg
Country
Russian Federation
City
St-Petersburg
Country
Russian Federation
City
Syktyvkar
Country
Russian Federation
City
Tomsk
Country
Russian Federation
City
Tyumen
Country
Russian Federation
City
Voronezh
Country
Russian Federation
City
Banska Bystrica
Country
Slovakia
City
Bratislava
Country
Slovakia
City
Malacky
Country
Slovakia
City
Presov
Country
Slovakia
City
Rimavska Sobota
Country
Slovakia
City
Sahy
Country
Slovakia
City
Trebisov
Country
Slovakia
City
Cape Town
Country
South Africa
City
Durban
Country
South Africa
City
Halfway
Country
South Africa
City
Johannesburg N/A
Country
South Africa
City
Johannesburg
Country
South Africa
City
Soweto, Johannesburg
Country
South Africa
City
Worcester
Country
South Africa
City
Cherkasy
Country
Ukraine
City
Dnepropetrovsk
Country
Ukraine
City
Donetsk
Country
Ukraine
City
Ivano Frankivsk
Country
Ukraine
City
Kharkov
Country
Ukraine
City
Kiev
Country
Ukraine
City
Kyiv
Country
Ukraine
City
Lviv
Country
Ukraine
City
Odesa
Country
Ukraine
City
Poltava
Country
Ukraine
City
Sumy
Country
Ukraine
City
Zaporozhye
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
26786577
Citation
Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G, Qiu R. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes. Diabetes Care. 2016 Mar;39(3):353-62. doi: 10.2337/dc15-1736. Epub 2016 Jan 19.
Results Reference
derived

Learn more about this trial

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

We'll reach out to this number within 24 hrs